Home › Companies › BRIDGEBIO PHARMA INC. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and BRIDGEBIO PHARMA INC.’s Form 8-K, filed June 23, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 20, 2025: 10 items on BRIDGEBIO PHARMA INC.’s Form 8-K, filed June 23, 2025: 5 approved · 5 passed (calculated).
Notable dissent: 2 directors (19.5%, 17.8% against); 1 say-on-pay vote (75.6% support); 1 equity or compensation plan (17.1% against); 1 other board item (24.1% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore BRIDGEBIO PHARMA INC. in the interactive database Compare manager voting policies
These tallies are BRIDGEBIO PHARMA INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 23, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Neil Kumar, Ph.D. | 154,328,316 | -- | -- | 2,495,765 | 17,052,893 | 98% | Passed (calculated) | — |
| Elect Director: Charles Homcy, M.D. | 145,872,389 | -- | -- | 10,951,692 | 17,052,893 | 93% | Passed (calculated) | — |
| Elect Director: Douglas A. Dachille | 128,916,085 | -- | -- | 27,907,996 | 17,052,893 | 82% | Passed (calculated) | — |
| Elect Director: Ronald J. Daniels | 151,032,065 | -- | -- | 5,792,016 | 17,052,893 | 96% | Passed (calculated) | — |
| Elect Director: Andrew W. Lo, Ph.D. | 126,242,281 | -- | -- | 30,581,800 | 17,052,893 | 80% | Passed (calculated) | — |
| 2. Non-binding Advisory Vote on Compensation of Named Executive Officers | 117,646,141 | 37,945,949 | 1,231,991 | -- | 17,052,893 | 76% | Approved | — |
| 3. Ratification of Appointment of Independent Registered Accounting Firm | 173,767,607 | 56,401 | 52,966 | -- | -- | 99.9% | Approved | — |
| 4. Approval of an Amendment and Restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan | 128,958,695 | 26,656,756 | 1,208,630 | -- | 17,052,893 | 83% | Approved | — |
| 5. Approval of an Amendment of the Company's Amended and Restated Certificate of Incorporation to include an officer exculpation provision that limits the liability of certain of its officers as permitted under current Delaware law | 151,194,026 | 5,574,758 | 55,297 | -- | 17,052,893 | 96% | Approved | — |
| 6. Approval of the Adjournment of the Annual Meeting to the Extent There are Insufficient Votes at the Annual Meeting to Approve Any of the Above Proposals | 131,826,931 | 41,878,620 | 171,423 | -- | -- | 76% | Approved | — |
Source: BRIDGEBIO PHARMA INC., Form 8-K, filed with the SEC on June 23, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
323 asset managers disclosed a vote on at least one BRIDGEBIO PHARMA INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 6 wordings of this item as funds reported it.
80% Majority: yes · of votes cast
Description as filed by funds: To elect five (5) nominees for director, Neil Kumar, Ph.D., Charles Homcy, M.D., Douglas A. Dachille, Ronald J. Daniels and Andrew W. Lo, Ph.D., to serve as Class III directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2027 and until their successors are duly elected and qualified: Andrew W. Lo, Ph.D.
BRIDGEBIO PHARMA INC.’s own tally for this item (“Elect Director: Andrew W. Lo, Ph.D.”): 126,242,281 for, 30,581,800 withheld, per its Form 8-K filed June 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 80% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 87 asset managers below reported 39,661,681 for, 8,916,531 withheld, 970,161 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,924,440 | 0 | 0 | 1,171 | For |
| Fidelity | 5,046,329 | 0 | 0 | 2,500 | For |
| BlackRock | 5,048,357 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,500,103 | 0 | 0 | 0 | For |
| State Street | 2,308,579 | 0 | 0 | 2,935 | For |
| Capital Group | 1,924,487 | 0 | 0 | 0 | For |
| Invesco | 0 | 0 | 0 | 1,597,746 | Withhold |
| NEW ECONOMY FUND | 1,557,279 | 0 | 0 | 0 | For |
| Charles Schwab | 1,297,106 | 0 | 0 | 0 | For |
| Principal | 295 | 0 | 0 | 893,294 | Withhold |
| AllianceBernstein | 0 | 0 | 0 | 861,977 | Withhold |
| Columbia Threadneedle | 849,002 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 839,739 | Withhold |
| T. Rowe Price | 739,580 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 615,753 | Withhold |
| Lord Abbett | 0 | 0 | 0 | 614,032 | Withhold |
| Equitable | 223,954 | 0 | 0 | 356,094 | Mixed |
| MUTUAL FUND SERIES TRUST | 532,192 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 527,869 | Withhold |
| PRIMECAP Odyssey Funds | 521,700 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 0 | 0 | 367,591 | 0 | Abstain |
| TIAA | 355,039 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 0 | 0 | 350,130 | Withhold |
| Bridge Builder Trust | 41,653 | 0 | 246,494 | 0 | Mixed |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 272,010 | Withhold |
Showing the 25 largest of 87 asset managers. All 87 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Description as filed by funds: To elect five (5) nominees for director, Neil Kumar, Ph.D., Charles Homcy, M.D., Douglas A. Dachille, Ronald J. Daniels and Andrew W. Lo, Ph.D., to serve as Class III directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2027 and until their successors are duly elected and qualified: Charles Homcy, M.D.
BRIDGEBIO PHARMA INC.’s own tally for this item (“Elect Director: Charles Homcy, M.D.”): 145,872,389 for, 10,951,692 withheld, per its Form 8-K filed June 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 87 asset managers below reported 44,160,220 for, 140,225 against, 4,798,820 withheld, 449,108 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,925,612 | 0 | 0 | 0 | For |
| Fidelity | 5,048,829 | 0 | 0 | 0 | For |
| BlackRock | 5,048,357 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,500,103 | 0 | 0 | 0 | For |
| State Street | 9,549 | 0 | 0 | 2,301,965 | Withhold |
| Capital Group | 1,924,487 | 0 | 0 | 0 | For |
| Invesco | 1,597,746 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 1,557,279 | 0 | 0 | 0 | For |
| Charles Schwab | 1,297,106 | 0 | 0 | 0 | For |
| Principal | 465,195 | 0 | 0 | 428,394 | Mixed |
| AllianceBernstein | 0 | 0 | 0 | 861,977 | Withhold |
| Columbia Threadneedle | 849,002 | 0 | 0 | 0 | For |
| American Century | 839,739 | 0 | 0 | 0 | For |
| T. Rowe Price | 739,580 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 615,753 | 0 | 0 | 0 | For |
| Lord Abbett | 614,032 | 0 | 0 | 0 | For |
| Equitable | 223,954 | 0 | 0 | 356,094 | Mixed |
| MUTUAL FUND SERIES TRUST | 532,192 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 527,869 | Withhold |
| PRIMECAP Odyssey Funds | 521,700 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 0 | 0 | 367,591 | 0 | Abstain |
| TIAA | 355,039 | 0 | 0 | 0 | For |
| Goldman Sachs | 350,130 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 288,147 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 272,010 | 0 | 0 | 0 | For |
Showing the 25 largest of 87 asset managers. All 87 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
82% Majority: yes · of votes cast
Description as filed by funds: To elect five (5) nominees for director, Neil Kumar, Ph.D., Charles Homcy, M.D., Douglas A. Dachille, Ronald J. Daniels and Andrew W. Lo, Ph.D., to serve as Class III directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2027 and until their successors are duly elected and qualified: Douglas A. Dachille
BRIDGEBIO PHARMA INC.’s own tally for this item (“Elect Director: Douglas A. Dachille”): 128,916,085 for, 27,907,996 withheld, per its Form 8-K filed June 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 87 asset managers below reported 41,597,771 for, 6,980,441 withheld, 970,161 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,924,440 | 0 | 0 | 1,171 | For |
| Fidelity | 5,046,329 | 0 | 0 | 2,500 | For |
| BlackRock | 5,048,357 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,500,103 | 0 | 0 | 0 | For |
| State Street | 2,308,579 | 0 | 0 | 2,935 | For |
| Capital Group | 1,924,487 | 0 | 0 | 0 | For |
| Invesco | 1,597,746 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 1,557,279 | 0 | 0 | 0 | For |
| Charles Schwab | 1,297,106 | 0 | 0 | 0 | For |
| Principal | 295 | 0 | 0 | 893,294 | Withhold |
| AllianceBernstein | 0 | 0 | 0 | 861,977 | Withhold |
| Columbia Threadneedle | 849,002 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 839,739 | Withhold |
| T. Rowe Price | 739,580 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 615,753 | Withhold |
| Lord Abbett | 0 | 0 | 0 | 614,032 | Withhold |
| Equitable | 223,954 | 0 | 0 | 356,094 | Mixed |
| MUTUAL FUND SERIES TRUST | 532,192 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 527,869 | Withhold |
| PRIMECAP Odyssey Funds | 521,700 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 0 | 0 | 367,591 | 0 | Abstain |
| TIAA | 355,039 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 0 | 0 | 350,130 | Withhold |
| Bridge Builder Trust | 41,653 | 0 | 246,494 | 0 | Mixed |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 272,010 | Withhold |
Showing the 25 largest of 87 asset managers. All 87 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: To elect five (5) nominees for director, Neil Kumar, Ph.D., Charles Homcy, M.D., Douglas A. Dachille, Ronald J. Daniels and Andrew W. Lo, Ph.D., to serve as Class III directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2027 and until their successors are duly elected and qualified: Neil Kumar, Ph.D.
BRIDGEBIO PHARMA INC.’s own tally for this item (“Elect Director: Neil Kumar, Ph.D.”): 154,328,316 for, 2,495,765 withheld, per its Form 8-K filed June 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 87 asset managers below reported 48,560,719 for, 140,225 against, 398,321 withheld, 449,108 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,925,612 | 0 | 0 | 0 | For |
| Fidelity | 5,048,829 | 0 | 0 | 0 | For |
| BlackRock | 5,048,357 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,500,103 | 0 | 0 | 0 | For |
| State Street | 2,311,514 | 0 | 0 | 0 | For |
| Capital Group | 1,924,487 | 0 | 0 | 0 | For |
| Invesco | 1,597,746 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 1,557,279 | 0 | 0 | 0 | For |
| Charles Schwab | 1,297,106 | 0 | 0 | 0 | For |
| Principal | 640,625 | 0 | 0 | 252,964 | Mixed |
| AllianceBernstein | 861,977 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 849,002 | 0 | 0 | 0 | For |
| American Century | 839,739 | 0 | 0 | 0 | For |
| T. Rowe Price | 739,580 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 615,753 | 0 | 0 | 0 | For |
| Lord Abbett | 614,032 | 0 | 0 | 0 | For |
| Equitable | 580,048 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 532,192 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 527,869 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 521,700 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 0 | 0 | 367,591 | 0 | Abstain |
| TIAA | 355,039 | 0 | 0 | 0 | For |
| Goldman Sachs | 350,130 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 288,147 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 272,010 | 0 | 0 | 0 | For |
Showing the 25 largest of 87 asset managers. All 87 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To elect five (5) nominees for director, Neil Kumar, Ph.D., Charles Homcy, M.D., Douglas A. Dachille, Ronald J. Daniels and Andrew W. Lo, Ph.D., to serve as Class III directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2027 and until their successors are duly elected and qualified: Ronald J. Daniels
BRIDGEBIO PHARMA INC.’s own tally for this item (“Elect Director: Ronald J. Daniels”): 151,032,065 for, 5,792,016 withheld, per its Form 8-K filed June 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 87 asset managers below reported 46,779,574 for, 2,319,691 withheld, 449,108 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,925,612 | 0 | 0 | 0 | For |
| Fidelity | 5,048,829 | 0 | 0 | 0 | For |
| BlackRock | 5,048,357 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,500,103 | 0 | 0 | 0 | For |
| State Street | 2,311,514 | 0 | 0 | 0 | For |
| Capital Group | 1,924,487 | 0 | 0 | 0 | For |
| Invesco | 1,597,746 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 1,557,279 | 0 | 0 | 0 | For |
| Charles Schwab | 1,297,106 | 0 | 0 | 0 | For |
| Principal | 465,195 | 0 | 0 | 428,394 | Mixed |
| AllianceBernstein | 0 | 0 | 0 | 861,977 | Withhold |
| Columbia Threadneedle | 849,002 | 0 | 0 | 0 | For |
| American Century | 839,739 | 0 | 0 | 0 | For |
| T. Rowe Price | 739,580 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 615,753 | 0 | 0 | 0 | For |
| Lord Abbett | 614,032 | 0 | 0 | 0 | For |
| Equitable | 223,954 | 0 | 0 | 356,094 | Mixed |
| MUTUAL FUND SERIES TRUST | 532,192 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 527,869 | Withhold |
| PRIMECAP Odyssey Funds | 521,700 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 0 | 0 | 367,591 | 0 | Abstain |
| TIAA | 355,039 | 0 | 0 | 0 | For |
| Goldman Sachs | 350,130 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 288,147 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 272,010 | 0 | 0 | 0 | For |
Showing the 25 largest of 87 asset managers. All 87 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
96% Approved · of votes cast
Description as filed by funds: To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to include an officer exculpation provision that limits the liability of certain of our officers as permitted under current Delaware law.
BRIDGEBIO PHARMA INC.’s own tally for this item (“5. Approval of an Amendment of the Company's Amended and Restated Certificate of Incorporation to include an officer exculpation provision that limits the liability of certain of its officers as permitted under current D”): 151,194,026 for, 5,574,758 against — passed, per its Form 8-K filed June 23, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the Officer Exculpation Amendment to the Company's Amended and Restated Certificate of Incorporation to include an officer exculpation provision that limits the liability of certain of its officers as permitted under current Delaware law.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 89 asset managers below reported 48,631,900 for, 827,758 against, 140,225 withheld, 26,311 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,924,441 | 1,171 | 0 | 0 | For |
| Fidelity | 5,048,829 | 0 | 0 | 0 | For |
| BlackRock | 5,048,357 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,500,103 | 0 | 0 | 0 | For |
| State Street | 2,310,160 | 1,354 | 0 | 0 | For |
| Capital Group | 1,924,487 | 0 | 0 | 0 | For |
| Invesco | 1,597,746 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 1,557,279 | 0 | 0 | 0 | For |
| Charles Schwab | 1,297,106 | 0 | 0 | 0 | For |
| Principal | 893,294 | 295 | 0 | 0 | For |
| AllianceBernstein | 861,977 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 849,002 | 0 | 0 | 0 | For |
| American Century | 839,739 | 0 | 0 | 0 | For |
| T. Rowe Price | 739,580 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 615,753 | 0 | 0 | 0 | For |
| Lord Abbett | 614,032 | 0 | 0 | 0 | For |
| Equitable | 580,048 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 532,192 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 527,869 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 521,700 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 367,591 | 0 | 0 | 0 | For |
| TIAA | 355,039 | 0 | 0 | 0 | For |
| Goldman Sachs | 350,130 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 228,041 | 60,106 | 0 | 0 | Mixed |
| DRIEHAUS MUTUAL FUNDS | 272,010 | 0 | 0 | 0 | For |
Showing the 25 largest of 89 asset managers. All 89 are in the interactive database (link above).
76% Approved · of votes cast
Description as filed by funds: To approve the adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve any of the above proposals.
BRIDGEBIO PHARMA INC.’s own tally for this item (“6. Approval of the Adjournment of the Annual Meeting to the Extent There are Insufficient Votes at the Annual Meeting to Approve Any of the Above Proposals”): 131,826,931 for, 41,878,620 against — passed, per its Form 8-K filed June 23, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 6 –Approval of the Adjournment of the Annual Meeting to the Extent There are Insufficient Votes at the Annual Meeting to Approve Any of the Above Proposals The Company's stockholders approved the adjournment of the Annual meeting to the extent that there were insufficient votes at the Annu…”
Support: 76% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 87 asset managers below reported 34,471,910 for, 14,898,027 against, 99,811 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,924,440 | 1,172 | 0 | 0 | For |
| Fidelity | 5,046,329 | 2,500 | 0 | 0 | For |
| BlackRock | 5,048,357 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,500,103 | 0 | 0 | 0 | For |
| State Street | 6,614 | 2,304,900 | 0 | 0 | Against |
| Capital Group | 0 | 1,924,487 | 0 | 0 | Against |
| Invesco | 1,597,746 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 0 | 1,557,279 | 0 | 0 | Against |
| Charles Schwab | 0 | 1,297,106 | 0 | 0 | Against |
| Principal | 428,394 | 465,195 | 0 | 0 | Mixed |
| AllianceBernstein | 861,977 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 849,002 | 0 | 0 | Against |
| American Century | 0 | 839,739 | 0 | 0 | Against |
| T. Rowe Price | 0 | 739,580 | 0 | 0 | Against |
| Delaware/Macquarie | 0 | 615,753 | 0 | 0 | Against |
| Lord Abbett | 0 | 614,032 | 0 | 0 | Against |
| Equitable | 580,048 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 532,192 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 527,869 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 521,700 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 367,591 | 0 | 0 | 0 | For |
| TIAA | 355,039 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 350,130 | 0 | 0 | Against |
| Bridge Builder Trust | 41,653 | 246,494 | 0 | 0 | Mixed |
| DRIEHAUS MUTUAL FUNDS | 0 | 272,010 | 0 | 0 | Against |
Showing the 25 largest of 87 asset managers. All 87 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
83% Approved · of votes cast
Description as filed by funds: To approve an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 5,000,000 shares.
BRIDGEBIO PHARMA INC.’s own tally for this item (“4. Approval of an Amendment and Restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan”): 128,958,695 for, 26,656,756 against — passed, per its Form 8-K filed June 23, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 4 - Approval of an Amendment and Restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan The Company's stockholders approved the amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan (th…”
Support: 83% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 93 asset managers below reported 39,674,641 for, 9,593,388 against, 140,225 withheld, 238,617 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,925,612 | 0 | 0 | 0 | For |
| Fidelity | 5,046,329 | 2,500 | 0 | 0 | For |
| BlackRock | 5,048,357 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,500,103 | 0 | 0 | 0 | For |
| State Street | 2,308,670 | 2,844 | 0 | 0 | For |
| Capital Group | 0 | 1,924,487 | 0 | 0 | Against |
| Invesco | 1,597,746 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 0 | 1,557,279 | 0 | 0 | Against |
| Charles Schwab | 1,297,106 | 0 | 0 | 0 | For |
| Principal | 428,689 | 464,900 | 0 | 0 | Mixed |
| AllianceBernstein | 861,977 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 849,002 | 0 | 0 | 0 | For |
| American Century | 0 | 839,739 | 0 | 0 | Against |
| T. Rowe Price | 0 | 739,580 | 0 | 0 | Against |
| Delaware/Macquarie | 0 | 615,753 | 0 | 0 | Against |
| Lord Abbett | 0 | 614,032 | 0 | 0 | Against |
| Equitable | 580,048 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 532,192 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 527,869 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 521,700 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 367,591 | 0 | 0 | 0 | For |
| TIAA | 355,039 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 350,130 | 0 | 0 | Against |
| Bridge Builder Trust | 101,759 | 186,388 | 0 | 0 | Mixed |
| DRIEHAUS MUTUAL FUNDS | 0 | 272,010 | 0 | 0 | Against |
Showing the 25 largest of 93 asset managers. All 93 are in the interactive database (link above).
Combines 15 wordings of this item as funds reported it.
76% Approved · of votes cast
Prior year: 93.5% for (June 21, 2024 meeting) ▼ 17.9 pts
Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.
BRIDGEBIO PHARMA INC.’s own tally for this item (“2. Non-binding Advisory Vote on Compensation of Named Executive Officers”): 117,646,141 for, 37,945,949 against — passed, per its Form 8-K filed June 23, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers.”
Support: 76% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,643,533 | 282,079 | 0 | 0 | For |
| Fidelity | 5,046,329 | 2,500 | 0 | 0 | For |
| BlackRock | 5,048,357 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,500,103 | 0 | 0 | 0 | For |
| State Street | 2,305,622 | 5,892 | 0 | 0 | For |
| Capital Group | 0 | 1,924,487 | 0 | 0 | Against |
| Invesco | 0 | 1,597,746 | 0 | 0 | Against |
| NEW ECONOMY FUND | 0 | 1,557,279 | 0 | 0 | Against |
| Charles Schwab | 0 | 1,297,106 | 0 | 0 | Against |
| Principal | 252,964 | 640,625 | 0 | 0 | Mixed |
| AllianceBernstein | 0 | 861,977 | 0 | 0 | Against |
| Columbia Threadneedle | 0 | 849,002 | 0 | 0 | Against |
| American Century | 0 | 839,739 | 0 | 0 | Against |
| T. Rowe Price | 0 | 739,580 | 0 | 0 | Against |
| Delaware/Macquarie | 0 | 615,753 | 0 | 0 | Against |
| Lord Abbett | 614,032 | 0 | 0 | 0 | For |
| Equitable | 223,954 | 356,094 | 0 | 0 | Mixed |
| MUTUAL FUND SERIES TRUST | 532,192 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 527,869 | 0 | 0 | Against |
| PRIMECAP Odyssey Funds | 0 | 521,700 | 0 | 0 | Against |
| FINANCIAL INVESTORS TRUST | 367,591 | 0 | 0 | 0 | For |
| TIAA | 355,039 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 350,130 | 0 | 0 | Against |
| Bridge Builder Trust | 41,653 | 246,494 | 0 | 0 | Mixed |
| DRIEHAUS MUTUAL FUNDS | 0 | 272,010 | 0 | 0 | Against |
Fund voting reports, all 88 managers: 32,772,839 for, 16,470,266 against, 238,617 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP | 22,055,375 | 0 | 0 | 0 | For |
| Aisling Capital Management LP | 6,068,125 | 0 | 0 | 0 | For |
| State Street | 5,025,926 | 69,601 | 0 | 0 | For |
| BlackRock | 4,836,353 | 37,089 | 0 | 0 | For |
| Janus Henderson | 4,675,040 | 70,961 | 0 | 0 | For |
| Frazier Life Sciences Management, L.P. | 3,800,457 | 0 | 0 | 0 | For |
| Capital Research Global Investors | 0 | 3,569,143 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 3,524,227 | 0 | 0 | 0 | For |
| Laurion Capital Management LP | 0 | 2,674,892 | 0 | 0 | Against |
| Kohlberg Kravis Roberts & Co. L.P. | 2,647,100 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 2,444,863 | 0 | 0 | Against |
| Fidelity | 1,970,696 | 0 | 0 | 0 | For |
| Invesco | 0 | 1,954,458 | 0 | 0 | Against |
| PICTET ASSET MANAGEMENT SA | 0 | 1,900,485 | 0 | 0 | Against |
| John Hancock | 0 | 1,887,568 | 0 | 0 | Against |
| SC US (TTGP), LTD. | 1,860,364 | 0 | 0 | 0 | For |
| FARALLON CAPITAL MANAGEMENT LLC | 0 | 1,742,600 | 0 | 0 | Against |
| Ensign Peak Advisors, Inc | 1,406,005 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 1,322,178 | 0 | 0 | Against |
| T. Rowe Price | 0 | 1,090,281 | 0 | 0 | Against |
| Catalio Capital Management, LP | 1,066,534 | 0 | 0 | 0 | For |
| PFM Health Sciences, LP | 0 | 1,023,713 | 0 | 0 | Against |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 0 | 894,011 | 0 | 0 | Against |
| American Century | 0 | 886,103 | 0 | 0 | Against |
| PRIMECAP MANAGEMENT CO/CA/ | 0 | 823,500 | 0 | 0 | Against |
Institutional-manager reports, all 256 managers: 65,105,025 for, 31,726,384 against, 140,225 withheld, 15,765 abstained, 6,260 not voted, 182,715 mixed. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Prior year: 99.9% for (June 21, 2024 meeting) ▲ 0.1 pts
Description as filed by funds: To ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.
BRIDGEBIO PHARMA INC.’s own tally for this item (“3. Ratification of Appointment of Independent Registered Accounting Firm”): 173,767,607 for, 56,401 against — passed, per its Form 8-K filed June 23, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 88 asset managers below reported 49,443,511 for, 0 against, 26,311 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,925,612 | 0 | 0 | 0 | For |
| Fidelity | 5,048,829 | 0 | 0 | 0 | For |
| BlackRock | 5,048,357 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,500,103 | 0 | 0 | 0 | For |
| State Street | 2,311,514 | 0 | 0 | 0 | For |
| Capital Group | 1,924,487 | 0 | 0 | 0 | For |
| Invesco | 1,597,746 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 1,557,279 | 0 | 0 | 0 | For |
| Charles Schwab | 1,297,106 | 0 | 0 | 0 | For |
| Principal | 893,589 | 0 | 0 | 0 | For |
| AllianceBernstein | 861,977 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 849,002 | 0 | 0 | 0 | For |
| American Century | 839,739 | 0 | 0 | 0 | For |
| T. Rowe Price | 739,580 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 615,753 | 0 | 0 | 0 | For |
| Lord Abbett | 614,032 | 0 | 0 | 0 | For |
| Equitable | 580,048 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 532,192 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 527,869 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 521,700 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 367,591 | 0 | 0 | 0 | For |
| TIAA | 355,039 | 0 | 0 | 0 | For |
| Goldman Sachs | 350,130 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 288,147 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 272,010 | 0 | 0 | 0 | For |
Showing the 25 largest of 88 asset managers. All 88 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 189,826,023 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 7.86% |
| 2 | Fidelity | 2.66% |
| 3 | BlackRock | 2.66% |
| 4 | JANUS INVESTMENT FUND | 1.32% |
| 5 | State Street | 1.22% |
| 6 | Capital Group | 1.01% |
| 7 | Invesco | 0.84% |
| 8 | NEW ECONOMY FUND | 0.82% |
| 9 | Charles Schwab | 0.68% |
| 10 | Principal | 0.47% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | VIKING GLOBAL INVESTORS LP | 11.62% |
| 2 | Aisling Capital Management LP | 3.20% |
| 3 | State Street | 2.68% |
| 4 | BlackRock | 2.57% |
| 5 | Janus Henderson | 2.50% |
| 6 | Frazier Life Sciences Management, L.P. | 2.00% |
| 7 | Capital Research Global Investors | 1.88% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 1.86% |
| 9 | Laurion Capital Management LP | 1.41% |
| 10 | Kohlberg Kravis Roberts & Co. L.P. | 1.39% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Viking Global Entities | 22,055,375 | 11.62% | Proxy statement (DEF 14A), proxy filed April 30, 2025 |
| Ali J. Satvat | 19,741,684 | 10.40% | Proxy statement (DEF 14A), proxy filed April 30, 2025 |
| Vanguard Group | 14,900,145 | 7.85% | Form 13F, quarter ended March 31, 2025 |
| BlackRock | 13,357,496 | 7.04% | Form 13F, quarter ended March 31, 2025 |
| KKR Genetic Disorder L.P. | 13,260,971 | 6.99% | Schedule 13D, filed May 14, 2025 |
| JANUS HENDERSON GROUP PLC | 13,179,013 | 6.94% | Schedule 13G, filed May 15, 2026 |
| VIKING GLOBAL INVESTORS LP | 11,842,434 | 6.24% | Schedule 13D, filed April 2, 2026 |
| Farallon Partners, L.L.C. | 10,023,341 | 5.28% | Schedule 13G, filed May 29, 2026 |
| NEIL KUMAR | 9,282,982 | 4.89% | Schedule 13G, filed April 16, 2026 |
| State Street | 5,749,619 | 3.03% | Form 13F, quarter ended March 31, 2025 |
Percentages above are of 189,826,023 shares outstanding, as reported by BRIDGEBIO PHARMA INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At BRIDGEBIO PHARMA INC.'s shareholder meeting held June 20, 2025, in the 2024-2025 proxy season, 323 asset managers reported votes on at least one of its 10 ballot items in their SEC Form N-PX filings, covering 3,313 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — BRIDGEBIO PHARMA INC.'s filing reports the proposal as approved, with 76% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: BRIDGEBIO PHARMA INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 23, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BRIDGEBIO PHARMA INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
BRIDGEBIO PHARMA INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “BRIDGEBIO PHARMA (BBIO) 2025 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/bridgebio-pharma-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.